Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
Condition: First-line Treatment of Non-clear Renal Cell Carcinoma Intervention: Drug: Fruquintinib combined with Serplulimab Sponsors: RenJi Hospital; Shanghai Zhongshan Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hospitals | Kidney Cancer | Renal Cell Carcinoma | Research | Study